Therapeutic Options and Critical Care Strategies in COVID-19 Patients: an Update
Journal of Practical Emergency Medicine,
Vol. 12 No. 1 (2025),
1 January 2025
,
Page e9
https://doi.org/10.22037/jpem.v12i1.48702
Abstract
he Coronavirus Disease 2019 (COVID-19) became the deadliest pandemic in the 21st century between 2019 and 2023. More than 700 million people were infected, and over 7 million individuals died due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). During the four-year pandemic, numerous drugs and treatment methods were evaluated in various clinical trials. Although vaccines emerged as the most effective means of disease modulation, identifying a safe and effective treatment regimen posed a significant challenge. This article reviews possible effective therapeutic drugs for COVID-19, their advantages, and side effects. Considering two main phases of disease progression (viral-mediated and immune system-mediated), antiviral drugs, immune-enhancing drugs, and anti-inflammatory agents can be used based on the clinical features and the disease severity. Among the most reliable antiviral agents for treating SARS-CoV-2 infection in high-risk patients with mild disease, as well as those with moderate to severe disease, are Paxlovid, remdesivir, and molnupiravir. Systemic corticosteroids are essential in the therapeutic regimen for moderate to severe COVID-19 patients who require supplemental oxygen. For anti-inflammatory and immunomodulatory agents, baricitinib and tocilizumab may be considered first-line treatments, while abatacept and infliximab can serve as alternative options. Additionally, other drugs have shown promising effects in randomized controlled trials but require further investigation before being established as part of the COVID-19 treatment protocol.
- COVID-19
- Critical Care
- Treatment
- Antiviral Therapy
How to Cite
References
1. Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. J Basic Microbiol. 2021;61(3):180-202.
2. (WCHC) WCHC. Wuhan Municipal Health and Health Commission’s Briefing on the Current Pneumonia Epidemic Situation in Our City 2019. Wuhan City Health Committee (WCHC). 2019.
3. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929-36.
4. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25(9).
5. Yavarian J, Shafiei-Jandaghi NZ, Sadeghi K, Shatizadeh Malekshahi S, Salimi V, Nejati A, et al. First Cases of SARS-CoV-2 in Iran, 2020: Case Series Report. Iran J Public Health. 2020;49(8):1564-8.
6. Organization WH. COVID-19 epidemiological update. 2023.
7. Organization WH. COVID-19 epidemiological update. 2024.
8. Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17-41.
9. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-8.
10. Coopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, et al. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med. 2021;49(4):598-622.
11. Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021;29(1):20-36.
12. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.
13. Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther. 2022;7(1):146.
14. Robinson PC, Liew DFL, Tanner HL, Grainger JR, Dwek RA, Reisler RB, et al. COVID-19 therapeutics: Challenges and directions for the future. Proc Natl Acad Sci U S A. 2022;119(15):e2119893119.
15. Bakheit AH, Darwish H, Darwish IA, Al-Ghusn AI. Remdesivir. Profiles Drug Subst Excip Relat Methodol. 2023;48:71-108.
16. Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev. 2020;34(1).
17. Avataneo V, de Nicolò A, Cusato J, Antonucci M, Manca A, Palermiti A, et al. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. J Antimicrob Chemother. 2020;75(7):1772-7.
18. Kumar I. A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of coronavirus disease. Journal of Drug Delivery and Therapeutics. 2021;11(1):121-9.
19. Lee TC, Murthy S, Del Corpo O, Senécal J, Butler-Laporte G, Sohani ZN, et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(9):1203-10.
20. Amstutz A, Speich B, Mentré F, Rueegg CS, Belhadi D, Assoumou L, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023;11(5):453-64.
21. Beckerman R, Gori A, Jeyakumar S, Malin JJ, Paredes R, Póvoa P, et al. Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis. Sci Rep. 2022;12(1):9622.
22. Ryoo S, Choi M, Yu SY, Yoon YK, Huh K, Joo EJ. The effects of remdesivir on mortality and the requirement for mechanical ventilation in patients with COVID-19: a systematic review stratified by disease severity. Korean J Intern Med. 2024;39(1):160-71.
23. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399(10339):1941-53.
24. Chen C, Fang J, Chen S, Rajaofera MJN, Li X, Wang B, et al. The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):672.
25. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020;76(4):370-6.
26. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-63.
27. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother. 2010;54(6):2517-24.
28. Kerber R, Lorenz E, Duraffour S, Sissoko D, Rudolf M, Jaeger A, et al. Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study. J Infect Dis. 2019;220(2):195-202.
29. Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G, et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv. 2020.
30. Sreekanth Reddy O, Lai WF. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. Chembiochem. 2021;22(6):939-48.
31. Korula P, Alexander H, John JS, Kirubakaran R, Singh B, Tharyan P, et al. Favipiravir for treating COVID-19. Cochrane Database Syst Rev. 2024;2(2):Cd015219.
32. Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol. 2021;50:17-22.
33. Syed YY. Molnupiravir: First Approval. Drugs. 2022;82(4):455-60.
34. Imran M, Kumar Arora M, Asdaq SMB, Khan SA, Alaqel SI, Alshammari MK, et al. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Molecules. 2021;26(19).
35. Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis. Ann Med. 2022;54(1):516-23.
36. Gao Y, Liu M, Li Z, Xu J, Zhang J, Tian J. Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2023;29(8):979-99.
37. Tian F, Feng Q, Chen Z. Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Antimicrob Agents. 2023;62(2):106870.
38. Sun M, Lai H, Huang J, Liu J, Li Y, Tian J, et al. Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients. J Antimicrob Chemother. 2023;78(9):2131-9.
39. Cheema HA, Abdul Rab S, Butt M, Jafar U, Shahid A, Rehman AU, et al. Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis. J Microbiol Immunol Infect. 2024;57(3):396-402.
40. Hashemian SMR, Sheida A, Taghizadieh M, Memar MY, Hamblin MR, Bannazadeh Baghi H, et al. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Biomed Pharmacother. 2023;162:114367.
41. Harris E. FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment. Jama. 2023;329(24):2118.
42. Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J Med Virol. 2023;95(2):e28441.
43. Zheng Q, Ma P, Wang M, Cheng Y, Zhou M, Ye L, et al. Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect. 2023;86(1):66-117.
44. Tian H, Yang C, Song T, Zhou K, Wen L, Tian Y, et al. Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID-19: An updated meta-analysis and trial sequential analysis. Rev Med Virol. 2023;33(5):e2473.
45. Tian F, Chen Z, Feng Q. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2023;95(4):e28732.
46. Ombelet S, Castanares-Zapatero D, Desimpel F, Hulstaert F, Stordeur S, Roberfroid D. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis. J Med Virol. 2024;96(2):e29434.
47. Jiang J, Li Y, Jiang Q, Jiang Y, Qin H, Li Y. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis. J Infect. 2024;89(2):106190.
48. Magro P, Zanella I, Pescarolo M, Castelli F, Quiros-Roldan E. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. Biomed J. 2021;44(1):43-53.
49. Dorward J, Gbinigie O, Cai T, Roberts NW, Garrett N, Hayward G, et al. The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review. Antivir Ther. 2020;25(7):365-76.
50. Amani B, Khanijahani A, Amani B, Hashemi P. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2021;24:246-57.
51. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-99.
52. Izcovich A, Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Kum E, et al. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. BMJ Open. 2022;12(3):e048502.
53. Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2021;93(1):481-90.
54. Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020;6:28.
55. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769-77.
56. Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020;26(7):917-21.
57. Yi W, Jia C, Yang Z, Fan H, Li M, Lv Z. Effect of umifenovir (arbidol) versus standard care on clinical outcome in patients with COVID-19: a retrospective cohort study. Ther Adv Respir Dis. 2023;17:17534666231183811.
58. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3s):S1-s46.
59. Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all? Front Immunol. 2014;5:674.
60. Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev. 2020;19(7):102559.
61. Guo Y, Tian X, Wang X, Xiao Z. Adverse Effects of Immunoglobulin Therapy. Front Immunol. 2018;9:1299.
62. World Health O. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. Geneva: World Health Organization; 2020 2020. Contract No.: WHO/2019-nCoV/clinical/2020.4.
63. Kwapisz D, Bogusławska J. Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients. Biomed Pharmacother. 2023;163:114851.
64. Gröning R, Walde J, Ahlm C, Forsell MNE, Normark J, Rasmuson J. Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: A retrospective cohort study. Int J Infect Dis. 2024;144:107046.
65. Sengupta P, Chattopadhyay S. Interferons in Viral Infections. Viruses. 2024;16(3).
66. Glanz A, Chakravarty S, Varghese M, Kottapalli A, Fan S, Chakravarti R, et al. Transcriptional and Non-Transcriptional Activation, Posttranslational Modifications, and Antiviral Functions of Interferon Regulatory Factor 3 and Viral Antagonism by the SARS-Coronavirus. Viruses. 2021;13(4).
67. Wang X, Tang Q, Li H, Jiang H, Xu J, Bergquist R, et al. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis. Int J Infect Dis. 2023;130:147-52.
68. Samuel CE. Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease. J Biol Chem. 2023;299(8):104960.
69. Pan YY, Wang LC, Yang F, Yu M. Interferon-lambda: New role in intestinal symptoms of COVID-19. World J Gastroenterol. 2023;29(13):1942-54.
70. Oleinik LA, Madonov PG, Pykhtina MB. [Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2]. Mol Biol (Mosk). 2023;57(2):307-15.
71. Xue C, Liu Z, Xiang H, Ye S, Ye Q. Efficacy of Interferon-Based Therapy for COVID-19: A Systematic Review and Meta-Analysis. Altern Ther Health Med. 2022;28(7):52-7.
72. Buchynskyi M, Kamyshna I, Lyubomirskaya K, Moshynets O, Kobyliak N, Oksenych V, et al. Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis. Front Immunol. 2023;14:1069894.
73. Chen WC, Hsu CK, Chen CY, Lai CC, Hung SH, Lin WT. Clinical efficacy and safety of interferon-β-containing regimens in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther. 2022;20(5):741-7.
74. Bahsoun A, Fakih Y, Zareef R, Bitar F, Arabi M. Corticosteroids in COVID-19: pros and cons. Front Med (Lausanne). 2023;10:1202504.
75. Wagner C, Griesel M, Mikolajewska A, Metzendorf MI, Fischer AL, Stegemann M, et al. Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence. Cochrane Database Syst Rev. 2022;11(11):Cd014963.
76. Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 2021;47(5):521-37.
77. Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W, Rochwerg B, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. Cmaj. 2020;192(27):E756-e67.
78. El-Saber Batiha G, Al-Gareeb AI, Saad HM, Al-Kuraishy HM. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022;30(4):1189-205.
79. Qadir N, Sahetya S, Munshi L, Summers C, Abrams D, Beitler J, et al. An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024;209(1):24-36.
80. Tsai DH, Harmon E, Goelen J, Barry HE, Chen LY, Hsia Y. Evaluating the Risk-Benefit Profile of Corticosteroid Therapy for COVID-19 Patients: A Scoping Review. Pharmacy (Basel). 2024;12(4).
81. Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020;34(6):1503-11.
82. McEvoy N, Lowry J, O'Dowd A, Curley GF, Fitzpatrick F. High-dose corticosteroid therapy in COVID-19: the RECOVERY trial. Lancet. 2024;403(10434):1337.
83. Rajan AK, Rashid M, Chandran VP, Hafis A, Kaur H, Poojari PG, et al. Efficacy of corticosteroids in COVID-19: An evidence-based approach from the published randomized controlled trials. Clinical Epidemiology and Global Health. 2025;33:101867.
84. Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, et al. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina (Kaunas). 2022;58(2).
85. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-44.
86. Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm. 2008;65(15):1413-8.
87. Preuss CV, Anjum F. Tocilizumab. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2025, StatPearls Publishing LLC.; 2025.
88. Keske Ş, Akyol M, Tanrıöver C, Özlüşen B, Akcan RE, Güler U, et al. Effectiveness of tocilizumab in non-intubated cases with COVID-19: a systematic review and meta-analysis. Infection. 2023;51(6):1619-28.
89. Boppana TK, Mittal S, Madan K, Mohan A, Hadda V, Guleria R. Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Monaldi Arch Chest Dis. 2022;92(4).
90. Ghosn L, Assi R, Evrenoglou T, Buckley BS, Henschke N, Probyn K, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023;6(6):Cd013881.
91. Durán-Sotuela A, Vázquez-García J, Relaño-Fernández S, Balboa-Barreiro V, Fernández-Tajes J, Blanco FJ, et al. An exploratory analysis of associations of genetic variation with the efficacy of tocilizumab in severe COVID-19 patients. A pharmacogenetic study based on next-generation sequencing. Front Pharmacol. 2024;15:1426826.
92. Ahmad A, Zaheer M, Balis FJ. Baricitinib. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2025, StatPearls Publishing LLC.; 2025.
93. Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12(8):e12697.
94. McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183.
95. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e1.
96. Albuquerque AM, Eckert I, Tramujas L, Butler-Laporte G, McDonald EG, Brophy JM, et al. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. Clin Microbiol Infect. 2023;29(1):13-21.
97. Song W, Sun S, Feng Y, Liu L, Gao T, Xian S, et al. Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(48):e36313.
98. Walker CP, Hurlock NP, Deb S. Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care. Diseases. 2024;12(5).
99. Conroy GM, Bauer SR, Pallotta AM, Duggal A, Wang L, Sacha GL. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study. Pharmacotherapy. 2024;44(1):28-38.
100. Troyer BS, Kovacic Scherrer N, Garavaglia J. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity. J Pharm Pract. 2024;37(3):632-6.
101. David P, Hen O, Ben-Shabbat N, Macleod T, Amital H, Watad A, et al. Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects. RMD Open. 2024;10(2).
102. Liu Y, Liu S, Liu L, Gong X, Liu J, Sun L, et al. Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. Rheumatol Ther. 2022;9(1):175-89.
103. Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, et al. Promising biological therapies for ulcerative colitis: A review of the literature. World J Gastrointest Pathophysiol. 2015;6(4):219-27.
104. Sarhan NM, Warda AEA, Ibrahim HSG, Schaalan MF, Fathy SM. Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome. Sci Rep. 2023;13(1):6456.
105. O'Halloran JA, Ko ER, Anstrom KJ, Kedar E, McCarthy MW, Panettieri RA, Jr., et al. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. Jama. 2023;330(4):328-39.
106. Amani B, Zareei S, Amani B, Zareei M, Zareei N, Shabestan R, et al. Artesunate, imatinib, and infliximab in COVID-19: A rapid review and meta-analysis of current evidence. Immun Inflamm Dis. 2022;10(6):e628.
107. Lin DY, Wang J, Anstrom KJ, LaVange LM, Wen J, Bozzette SA, et al. Efficacy of infliximab, abatacept, and cenicriviroc for the treatment of adults hospitalized with COVID-19 pneumonia. Int J Infect Dis. 2024;146:107168.
108. Bonelli M, Scheinecker C. How does abatacept really work in rheumatoid arthritis? Curr Opin Rheumatol. 2018;30(3):295-300.
109. Balevic SJ, Benjamin DK, Jr., Powderly WG, Smith PB, Gonzalez D, McCarthy MW, et al. Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial. JAMA Network Open. 2024;7(4):e247615.
- Abstract Viewed: 52 times
- PDF Downloaded: 67 times
